EUVIMEDEUVIMED entdecken
Crossref

Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development

Camile Delva, Todd F Pearson, John E Harris

Cutis · 2024

DOI: 10.12788/cutis.0995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cutis, 2024. Verfasst von Camile Delva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Camile Delva is from the CUNY School of Medicine, New York, New York. Drs. Pearson and Harris are from the Department of Dermatology, UMass Chan Medi…. Hauptthemen laut MEDLINE: Vitiligo, Drug Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VitiligoDrug DevelopmentHumansDermatologic AgentsMolecular Targeted Therapy

Substanzen

Dermatologic Agents

Autor:innen und Institutionen

  • Camile Delva is from the CUNY School of Medicine, New York, New York. Drs. Pearson and Harris are from the Department of Dermatology, UMass Chan Medical School, Worcester.

Zitieren

APA

Delva, C., Pearson, T. F., & Harris, J. E. (2024). Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. https://doi.org/10.12788/cutis.0995

Vancouver

Delva C, Pearson TF, Harris JE. Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development. Cutis. 2024. doi:10.12788/cutis.0995

BibTeX
@article{Delva2024,
  author = {Delva, Camile and Pearson, Todd F and Harris, John E},
  title = {Advancements in Targeted Therapies for Vitiligo: Prioritizing Equity in Drug Development},
  journal = {Cutis},
  year = {2024},
  doi = {10.12788/cutis.0995}
}
Kostenlos starten →